On April 11, 2024, Merck & Co., Inc announced that it has received a shareholder proposal from Kenneth Steiner requesting the Company board of directors to take such steps as may be necessary to permit written consent by the shareholders entitled to cast the minimum number of votes that would be necessary to authorize an action at a meeting at which all shareholders entitled to vote thereon were present and voting. This includes shareholder ability to initiate any appropriate topic for written consent. In addition, the Company urged the shareholders to vote against the proposal at its annual general meeting of shareholders scheduled to be held on May 28, 2024.